Senior Medical Physicist
About the job
- The candidate must be located in or willing to relocate to Longview, Texas, or the surrounding area.
- A master's or PhD in Medical Physics or a closely related field is required.
- At least 3 years of clinical experience in addition to a CAMPEP-accredited residency is required.
- Certification in Radiation Oncology Physics by the American Board of Radiology or another alternative certifying body is required; candidates who are not certified must be eligible for board certification and achieve it within 3 years of hire.
- The candidate must apply for and maintain relevant state licensing or registration required to work as a medical physicist at the clinical site in a timely manner.
- The candidate must meet and maintain vendor credentialing requirements for full access to client sites, which may include identification, background checks, drug screens, immunizations, annual tuberculosis testing, and healthcare training.
- The candidate must be able to work with controlled technology in accordance with United States export control law.
- Work at the clinic site with Cancer Care Leadership to ensure the safe interpretation, delivery, operation, and monitoring of radiation safety policies, procedures, standards, and equipment for Radiation Oncology Services.
- Ensure high-quality radiation therapy and provide staff with education, training, and oversight to minimize radiation exposure.
- Implement and abide by customer service standards and support patient safety and other appropriate safety practices.
- Support and demonstrate family-centered care principles when interacting with patients, their families, and coworkers.
- Calibrate dose meters, including dosimetric inter-comparisons for quality assurance, and radiation equipment, including accelerator monitor unit calibration; acquire beam data for treatment planning.
- Prepare data for treatment planning systems and develop or improve dose measurement systems, protocols, and dosimetry software, including spreadsheets and databases.
- Ensure compliance with federal, state, and organizational radiation safety regulations.
- Participate in developing organizational performance-improvement activities, policies and procedures, and standards of practice to meet regulatory requirements.
- Assist with acceptance testing and commissioning of new machines, and acceptance testing and recommissioning after major maintenance.
- Perform individual treatment planning, dosimetry calculations, and physics-component treatment planning reviews.
- Provide physics consultation to radiation oncology personnel and radiation oncologists on patient care and treatment.
- Ensure routine verification of the department treatment planning system.
- Collaborate with the information services department and provide software management of the department planning system.
- Assist with planning and shielding calculations for new radiation facilities and programs.
- Interpret regulatory changes and prepare documentation summaries for integration into departmental operations.
- Provide dosimetry checks following source changes.
- Assist with selecting and acquiring sources for permanent implant techniques.
- Collaborate with the department director and Physics director on clinical education, training, and competency evaluations for medical physics, dosimetry, and therapy staff.
- Passing the American Board of Radiology Part I and possibly Part II examinations is preferred.
- Experience with High Dose Rate programs and Stereotactic Radiosurgery programs is preferred.
- Computer system administration experience with patient record-and-verify database applications is desirable.
About the company
Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
1948
Get referred to Varian
See people who can refer or advise you
Simplify's Take
What believers are saying
- ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
- FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
- Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.
What critics are saying
- RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
- Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
- If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.
What makes Varian unique
- Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
- Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
- TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Health Insurance
Dental Insurance
Vision Insurance
Wellness Program
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster
Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.
Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.
Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.
Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.